Journal
NATURE MEDICINE
Volume 7, Issue 6, Pages 738-741Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/89121
Keywords
-
Funding
- NHLBI NIH HHS [R01 HL-43364] Funding Source: Medline
Ask authors/readers for more resources
Long-term solid-organ allografts typically develop diffuse arterial intimal lesions (graft arterial disease; GAD), consisting of smooth-muscle cells (SMC), extracellular matrix and admired mononuclear leukocytes. GAD eventually culminates in vascular stenosis and ischemic graft failure. Although the exact mechanisms are unknown, chronic low-level alloresponses likely induce inflammatory cells and/or dysfunctional vascular wall cells to secrete growth factors that promote SMC intimal recruitment, proliferation and matrix synthesis(1-3). Although prior work demonstrated that the endothelium and medial SMCs lining GAD lesions in cardiac allografts are donor-derived, the intimal SMC origin could not be determined(4). They are generally presumed to originate from the donor media(5), leading to interventions that target donor medial SMC proliferation, with limited efficacy(6,7). However, other reports indicate that allograft vessels may contain host-derived endothelium and SMCs (refs. 8,9). Moreover, subpopulations of bone-marrow and circulating cells can differentiate into endothelium(10,11), and implanted synthetic vascular grafts are seeded by host SMCs and endothelium(12,13). Here we used murine aortic transplants to formally identify the source of SMCs in GAD lesions. Allografts in beta -galactosidase transgenic recipients showed that intimal SMCs derived almost exclusively from host cells. Bone-marrow transplantation of beta -galactosidase-expressing cells into aortic allograft recipients demonstrated that intimal cells included those of marrow origin. Thus, smooth-muscle-like cells in GAD lesions can originate from circulating bone-marrow-derived precursors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available